Visit our new Alternative Investment section.Click here

Less Ads, More Data, More Tools Register for FREE

MaxCyte shares trading for last time in London

Wed, 25th Jun 2025 12:33

(Sharecast News) - MaxCyte confirmed on Wednesday that trading of its shares on London's AIM market would cease at the close of trading, with the cancellation of its AIM listing taking effect at 0700 BST on Thursday.

It said the decision followed shareholder approval at the company's annual general meeting on 18 June.

The cell engineering company, which provides platform technologies for the development of next-generation cell therapeutics, said it would retain its listing on the Nasdaq Global Select Market in the United States, where its shares would continue to trade under the ticker MXCT.

MaxCyte noted that following the delisting, there would no longer be a public market in the UK for its common stock.

At 1149 BST, shares in MaxCyte were down 5.94% in London, at 150.5p.

Reporting by Josh White for Sharecast.com.


Shares in this article

Related News

MaxCyte and Ori Biotech partner to boost cell therapy manufacturing
11 Jun 2025

MaxCyte and Ori Biotech partner to boost cell therapy manufacturing

(Alliance News) - MaxCyte Inc and Ori Biotech Ltd on Wednesday announced a collaboration aimed at boosting efficiency and scalability in cell and gene...

MaxCyte enters collaboration with Ori Biotech
11 Jun 2025

MaxCyte enters collaboration with Ori Biotech

(Sharecast News) - MaxCyte announced a strategic collaboration with Ori Biotech on Wednesday, to improve the efficiency and scalability of cell therap...